Journal of Law and the Biosciences

期刊全称Journal of Law and the Biosciences
期刊缩写J. Law Biosci.
涉及主题政治学医学法学生物计算机科学经济心理学社会学哲学业务遗传学病理内科学历史数学地理考古精神科认识论
期刊介绍

The Journal of Law and the Biosciences (JLB) is the first fully Open Access peer-reviewed legal journal focused on the advances at the intersection of law and the biosciences. A co-venture between Duke University, Harvard University Law School, and Stanford University, and published by Oxford University Press, this open access, online, and interdisciplinary academic journal publishes cutting-edge scholarship in this important new field. The Journal contains original and response articles, essays, and commentaries on a wide range of topics, including bioethics, neuroethics, genetics, reproductive technologies, stem cells, enhancement, patent law, and food and drug regulation. JLB is published as one volume with three issues per year with new articles posted online on an ongoing basis.

期刊ISSNprint: 2053-9711
历年影响因子
2024年 2023年 2022年 2021年 2020年 2019年 2018年 2017年
2.53.46.0663.5832.2752.43100
历年发表/被引量
年份20252024202320222021202020192018201720162015201420132012
发表量13313336369015304468583400
被引量3911132154411151246723455360252107531811
h-Index0
自引率4.00%
涉及的研究领域Medicine-Medicine (miscellaneous)
中科院2025年分区 ?
大类小类TOP期刊综述期刊
2区2区 医学:法
3区伦理学
3区法学
3区医学:伦理
WOS期刊分区

JCR学科分类

JCR分区学科名称收录数据库JCR分区分区排名
ETHICSSSCIQ117/77
LAWSSCIQ130/434
MEDICAL ETHICSSCIEQ26/23
MEDICINE, LEGALSCIEQ15/22

JCI学科分类

JCI分区学科名称收录数据库JCI分区分区排名
ETHICSSSCIQ19/77
LAWSSCIQ149/434
MEDICAL ETHICSSCIEQ12/23
MEDICINE, LEGALSCIEQ11/22
期刊主页https://academic.oup.com/jlb
投稿网址https://mc.manuscriptcentral.com/jlb
出版商Oxford University Press
出版国家(地区)United Kingdom
出版语言English
每年出版文章数66
Gold OA文章占比92.14%
原创研究文献占比
(排除综述)
100.00%
SCI收录类型

Science Citation Index Expanded (SCIE)

Social Science Citation Index (SSCI)

Scopus (CiteScore)

Directory of Open Access Journals (DOAJ)

PubMed链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2053-9711%5BISSN%5D
平均审稿周期13 Weeks
相关链接

您可以在上述网站查看该期刊的网友互动,及期刊影响力的其它指标。

注:上述信息均来源于网络,仅供查考,如有遗漏或信息错误,欢迎 向我反馈